Cargando…
First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441301/ http://dx.doi.org/10.1186/1742-4690-9-S2-O52 |
| _version_ | 1782243259432566784 |
|---|---|
| author | Walsh, SR Seaman, MS Johnson, JA Tucker, RP Krause, KH Weijtens, M Pau, MG Goudsmit, J Dolin, R Barouch, DH Baden, LR |
| author_facet | Walsh, SR Seaman, MS Johnson, JA Tucker, RP Krause, KH Weijtens, M Pau, MG Goudsmit, J Dolin, R Barouch, DH Baden, LR |
| author_sort | Walsh, SR |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3441301 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2012 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-34413012012-09-18 First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine Walsh, SR Seaman, MS Johnson, JA Tucker, RP Krause, KH Weijtens, M Pau, MG Goudsmit, J Dolin, R Barouch, DH Baden, LR Retrovirology Oral Presentation BioMed Central 2012-09-13 /pmc/articles/PMC3441301/ http://dx.doi.org/10.1186/1742-4690-9-S2-O52 Text en Copyright ©2012 Walsh et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Oral Presentation Walsh, SR Seaman, MS Johnson, JA Tucker, RP Krause, KH Weijtens, M Pau, MG Goudsmit, J Dolin, R Barouch, DH Baden, LR First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine |
| title | First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine |
| title_full | First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine |
| title_fullStr | First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine |
| title_full_unstemmed | First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine |
| title_short | First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine |
| title_sort | first-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 hvr48 (rad5hvr48) hiv-1 vaccine |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441301/ http://dx.doi.org/10.1186/1742-4690-9-S2-O52 |
| work_keys_str_mv | AT walshsr firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT seamanms firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT johnsonja firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT tuckerrp firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT krausekh firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT weijtensm firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT paumg firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT goudsmitj firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT dolinr firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT barouchdh firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine AT badenlr firstinhumanphase1trialofthesafetyandimmunogenicityofarecombinantadenovirusserotype5hvr48rad5hvr48hiv1vaccine |